TransMedics Group, Inc. Form 8-K Summary
Business context and reporting period
TransMedics Group, Inc. filed a Form 8-K dated June 4, 2020, reporting results from its 2020 Annual Meeting of Shareholders. The filing was signed on June 8, 2020. The company is incorporated in Massachusetts and its common stock trades on Nasdaq under the symbol TMDX.
Financial metrics and liquidity
This filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material changes and shareholder votes
- Shareholders elected Waleed H. Hassanein, M.D.; James R. Tobin; Edward M. Basile; Thomas J. Gunderson; Edwin M. Kania; and David Weill, M.D. as directors, each to serve until the 2021 annual meeting or until a successor is elected and qualified, or earlier departure.
- Votes included 5,248,909 broker non-votes for each director nominee. Votes in favor ranged from 10,082,911 to 11,298,981; votes withheld ranged from 53,186 to 1,269,256.
- Shareholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, with 16,575,996 votes for, 12,545 against, and 12,535 abstentions.
Guidance, outlook, risks, and unusual items
The filing provides no financial guidance, operating outlook, management commentary, risk updates, contingencies, or unusual financial items. Its disclosures are limited to annual meeting voting results.
Key facts for investors to verify
- Confirm the election and continued service of all six listed directors.
- Review the substantial broker non-vote totals in the director elections.
- Confirm shareholder ratification of PricewaterhouseCoopers LLP for fiscal 2020.
- Consult the company’s periodic financial filings for financial performance, liquidity, debt, and outlook information not included in this Form 8-K.